Overview


According to FutureWise analysis the market for High Blood Pressure Drugs (Hypertension) in 2023 is US$ 25.14 billion, and is expected to reach US$ 33.41 billion by 2031 at a CAGR of 3.62%.

FutureWise Market Research has illustrated a report on the market. The report provides an in-depth anatomy of the market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.

The High Blood Pressure Drugs (Hypertension) market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Eli Lilly
  • Pfizer
  • Bayer
  • Symplmed
  • Novartis
  • Merck
  • Sanofi
  • Boryung
  • Reata Pharmaceuticals
  • Lung Biotechnology

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • ACEI
  • CCB
  • ARB

By Application

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the market by product type, by application and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
  • To record and evaluate the competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global High Blood Pressure Drugs (Hypertension) Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global High Blood Pressure Drugs (Hypertension) Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of High Blood Pressure Drugs (Hypertension) Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global High Blood Pressure Drugs (Hypertension) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global High Blood Pressure Drugs (Hypertension) Market, By Product Type Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. ACEI
        2. CCB
        3. ARB

  • 8.   Global High Blood Pressure Drugs (Hypertension) Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 9.   North America High Blood Pressure Drugs (Hypertension) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 10.   Latin America High Blood Pressure Drugs (Hypertension) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 11.   Europe High Blood Pressure Drugs (Hypertension) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 12.   Asia Pacific High Blood Pressure Drugs (Hypertension) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 13.   Middle East and Africa High Blood Pressure Drugs (Hypertension) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 14.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)

    •    1. Eli Lilly
         1.1. Company Overview (HQ, Business Segments, Employee Strength)
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
         2. Pfizer
         2.1. Company Overview (HQ, Business Segments, Employee Strength)
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
         3. Bayer
         3.1. Company Overview (HQ, Business Segments, Employee Strength)
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
         4. Symplmed
         4.1. Company Overview (HQ, Business Segments, Employee Strength)
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
         5. Novartis
         5.1. Company Overview (HQ, Business Segments, Employee Strength)
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
         6 . Merck
         6.1. Company Overview (HQ, Business Segments, Employee Strength)
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
         7. Sanofi
         7.1. Company Overview (HQ, Business Segments, Employee Strength)
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
         8. Boryung
         8.1. Company Overview (HQ, Business Segments, Employee Strength)
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
         9. Reata Pharmaceuticals
         9.1. Company Overview (HQ, Business Segments, Employee Strength)
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Lung Biotechnology
         10.1. Company Overview (HQ, Business Segments, Employee Strength)
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.  Pre and Post Covid-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11